Last reviewed · How we verify
Spironolactone and furosemide
Spironolactone blocks aldosterone to retain potassium while furosemide inhibits sodium reabsorption to promote diuresis, together managing fluid overload and electrolyte balance.
Spironolactone blocks aldosterone to retain potassium while furosemide inhibits sodium reabsorption to promote diuresis, together managing fluid overload and electrolyte balance. Used for Heart failure with fluid overload, Edema associated with liver cirrhosis or renal disease, Hypertension with concurrent need for potassium conservation.
At a glance
| Generic name | Spironolactone and furosemide |
|---|---|
| Sponsor | University of Padova |
| Drug class | Combination diuretic (potassium-sparing diuretic + loop diuretic) |
| Target | Aldosterone receptor (spironolactone); Na-K-Cl cotransporter (furosemide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that reduces sodium and water reabsorption in the collecting duct while conserving potassium. Furosemide is a loop diuretic that inhibits the Na-K-Cl cotransporter in the thick ascending limb, promoting significant sodium, chloride, and water excretion. Together, they provide complementary diuretic effects while offsetting each other's electrolyte disturbances—furosemide-induced hypokalemia is counteracted by spironolactone's potassium retention.
Approved indications
- Heart failure with fluid overload
- Edema associated with liver cirrhosis or renal disease
- Hypertension with concurrent need for potassium conservation
Common side effects
- Hyperkalemia
- Hyponatremia
- Dehydration
- Hypotension
- Gynecomastia (spironolactone)
- Ototoxicity (furosemide at high doses)
Key clinical trials
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients (NA)
- To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation. (NA)
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (PHASE1, PHASE2)
- Risk Stratification of Heart Failure in Cardiomyopathies. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone and furosemide CI brief — competitive landscape report
- Spironolactone and furosemide updates RSS · CI watch RSS
- University of Padova portfolio CI